Serum Exosomal Long Noncoding RNAs as Potential Biomarkers for Lung Cancer Diagnosis

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology1,000 enrolled

Overview

The study is to investigate the sensitivity and specificity of serum exosome noncoding RNA as a biomarker for the diagnosis of lung cancer

Conventional tumor markers for non-invasive diagnosis of Lung cancer (LC) exhibit insufficient sensitivity and specificity to facilitate detection of early lung cancer (ELC). The investigators aimed to identify ELC-specific exosomal lncRNA biomarkers that are highly sensitive and stable for the non-invasive diagnosis of ELC.Hence, in the present study, exosomes from the plasma of five healthy individuals and 30 LC patients and from culture media of four human bronchial epithelial cells and four cancer cells were isolated. Exosomal RNA profiling was performed using RNA sequencing to identify LC specific exosomal lncRNAs.

Study Type

OBSERVATIONAL

Enrollment

1,000

Conditions

Lung Cancer (Diagnosis)

Interventions

collect samplesDIAGNOSTIC_TEST

collect serum samples and clinical features

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Subjects are willing to sign the informed consent form; * Normal subjects have no evidence of any disease; * Lung cancer patients are 18 to 75 years old, diagnosed as lung cancer by histopathology or cytopathology Exclusion Criteria: * People are unwilling to sign the informed consent form; * Patients with heart disease, rheumatic disease, allergic disease, COPD, pulmonary fibrosis, diabetes, thyroid disease, liver, kidney, brain disease and hematopoietic system disease; * Pregnant or lactating women; * Patients did not cooperate or participate in other clinical trials

Locations (1)

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, China

Outcomes

Primary Outcomes

The expression levels of serum exosome long non-coding RNA

Time frame: the first day subjects are enrolled the outcome will be assessed；up to three years after the completion of the study

the expression levels of tumor biomarkers such as CEA, NSE, SCC, CYFR2A-1

Time frame: the first day subjects are enrolled the outcome will be assessed；up to three years after the completion of the study

the CT scans of the lung for the patients

Time frame: the first day subjects are enrolled the outcome will be assessed；up to three years after the completion of the study

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.